The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  White, Michael T ^a   Griffin, Jamie T ^a   Ghani, Azra C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIGEN;

ARTICLE; CROSS-SECTIONAL STUDY; DISEASE SIMULATION; DISEASE TRANSMISSION; ERYTHROCYTE; HUMAN; IMMUNE RESPONSE; LONGITUDINAL STUDY; MALARIA FALCIPARUM; MICROORGANISM DETECTION; PLASMODIUM FALCIPARUM; REINFECTION; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC);

EPIDEMIOLOGIC METHODS; HUMANS; MALARIA, FALCIPARUM; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; RECURRENCE;

EID: 84881178835     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-278     Document Type: Article

References (44)

1. RTS, S clinical trials partnership: first results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BGNO, Doucka Y, Flamen A, Mordmueller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, et al. N Eng J Med 2011 365 1863 1875
2. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AVS, PLoS Med 2004 1 128 136
3. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, et al. Science 2011 334 475 480 10.1126/science.1211548 21903775
4. Protective immunity to pre-erythrocytic stage malaria. Schwenk RJ, Richie TL, Trends Parasitol 2011 27 306 314 10.1016/j.pt.2011.02.002 21435951
5. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Vanderberg JP, Frevert U, Int J Parasitol 2004 34 991 996 10.1016/j.ijpara.2004.05.005 15313126
6. Plasmodium sporozoites trickle out of the injection site. Yamauchi LM, Coppi A, Snounou G, Sinnis P, Cell Microbiol 2007 9 1215 1222 10.1111/j.1462-5822.2006.00861.x 17223931
7. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. Murphy JR, Baqar S, Davis JR, Herrington DA, Clyde DF, J Clin Microbiol 1989 27 1434 1437 2671011
8. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Offeddu V, Thathy V, Marsh K, Matuschewski K, Int J Parasitol 2012 42 535 548 10.1016/j.ijpara.2012.03.011 22561398
9. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. Kebaier C, Voza T, Vanderberg J, PloS Path 2009 5 1000399 10.1371/journal.ppat.1000399
10. Invitro activity of CD4+ and CD8+ lymphocytes-T from mice immunized with a synthetic malaria peptide. Renia L, Marussig MS, Grillot D, Pied S, Corradin G, Miltgen F, Delgiudice G, Mazier D, Proc Nat Acad Sci USA 1991 88 7963 7967 10.1073/pnas.88.18.7963 1680235
11. Genetically attenuated parasite vaccines induce contact-dependent CD8(+) T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, Wang R, J Immunol 2009 183 5870 5878 10.4049/jimmunol.0900302 19812194
12. Plasmodium falciparum infected Anopheles-stephensi inconsistently transmit malaria to humans. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, Paul CF, Beaudoin RL, Hoffman SL, AmJTrop Med Hyg 1990 43 441 445
13. Molineaux L, The Garki Project Geneva: World Health Organization 1980
14. Mathematical models for transmission and control of malaria. Dietz K, Wernsdorfer WH, McGregor I, Malaria Principles and practice of malariology 1988 2 1091 1133
15. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Tall A, Sokhna C, Perraut R, Fontenille D, Marrama L, Ly AB, Sarr FD, Toure A, Trape JF, Spiegel A, Rogier C, Druilhe P, Malar J 2009 8 161 10.1186/1475-2875-8-161 19604389
16. A quantitative analysis of transmission efficiency versus intensity for malaria. Smith DL, Drakeley CJ, Chiyaka C, Hay SI, Nat Comm 2010 1 108 10.1038/ncomms1107
17. Immune effector mechanisms in malaria. Marsh K, Kinyanjui S, Parasite Immunol 2006 28 51 60 10.1111/j.1365-3024.2006.00808.x 16438676
18. Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections. Doolan DL, Hoffman SL, Phil Tran Roy Soc B 1997 352 1361 1367 10.1098/rstb.1997.0121
19. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L, Tanner M, AmJTrop Med Hyg 2006 75 11 18
20. Uninfected mosquito bites confer protection against infection with malaria parasites. Donovan MJ, Messmore AS, Scrafford DA, Sacks DL, Kamhawi S, McDowell MA, Infect Immunity 2007 75 2523 2530 10.1128/IAI.01928-06
21. Host-mediated regulation of superinfection in malaria. Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA, Epiphanio S, Sullivan D, Roy C, Newbold CI, Drakesmith H, Mota MM, Nat Med 2011 17 732 U126 10.1038/nm.2368 21572427
22. The distribution of Plasmodium falciparum infection durations. Bretscher MT, Maire N, Chitnis N, Felger I, Owusu-Agyei S, Smith T, Epidemics 2011 3 109 118 10.1016/j.epidem.2011.03.002 21624782
23. Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Sokhna CS, Rogier C, Dieye A, Trape JF, AmJTrop Med Hyg 2000 62 266 270
24. Study of the aggressiveness of Anopheles gambiae A in relation to the age and sex of human subjects. Carnevale P, Frezil JL, Bosseno MF, Pont FL, Lancien J, Bull World Health Organ 1976 56 147 154
25. The relationship of host size to feeding by mosquitos of the Anopheles-gambiae Giles complex (Diptera, Culicidae). Port GR, Boreham PFL, Bryan JH, Bull Entomol Res 1980 70 133 144 10.1017/S0007485300009834
26. Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. White MT, Griffin JT, Drakeley CJ, Ghani AC, Malar J 2010 9 82 10.1186/1475-2875-9-82 20331863
27. Immune-responses to sporozoite antigens and their relationship to naturally acquired-immunity to malaria. Greenwood BM, Bull World Health Organ 1990 68 184 190 2094586
28. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria? Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS, Trop Med Int Health 2008 13 229 237 10.1111/j.1365-3156.2007.01994.x 18304269
29. Sporozoite antibodies and malaria in children in a rural area of the Gambia. Snow RW, Shenton FC, Lindsay SW, Greenwood BM, Bennett S, Wheeler J, Delgiudice G, Verdini AS, Pessi A, Ann Trop Med Parasitol 1989 83 559 568 2694982
30. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. Hoffman SL, Wistar R, Ballou WR, Hollingdale MR, Wirtz RA, Schneider I, Marwoto HA, Hockmeyer WT, N Eng J Med 1986 315 601 606 10.1056/NEJM198609043151001
31. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. White MT, Griffin JT, Riley EM, Drakeley CJ, Moormann AM, Odada Sumba P, Kazura JW, Ghani AC, John CJ, Proc Roy Soc B 2010 278 1298 1305
32. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW, AmJTrop Med Hyg 2005 73 222 228
33. Factors influencing resistance to reinfection with Plasmodium falciparum. Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, Tiga H, Deloron P, AmJTrop Med Hyg 1999 61 926 931
34. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4?+?T cells but does not protect against experimental Plasmodium falciparum infection. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon I-K, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr, Vaccine 2010 28 5135 5144 10.1016/j.vaccine.2009.08.046 19737527
35. Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population. Marsh K, Hayes RH, Carson DC, Otoo L, Shenton F, Byass P, Zavala F, Greenwood BM, Trans R Soc Trop Med Hyg 1988 82 532 537 10.1016/0035-9203(88) 90495-6 2475928
36. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois M-C, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P, Lancet Inf Dis 2011 11 102 109 10.1016/S1473-3099(10)70262-0
37. Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. Perraut R, Marrama L, Diouf B, Fontenille D, Tall A, Sokhna C, Trape JF, Garraud O, Mercereau-Puijalon O, J Inf Dis 2003 188 1940 1950 10.1086/379838
38. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC, J Inf Dis 2011 204 19 26 10.1093/infdis/jir223
39. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P, Felgner PL, Doolan DL, Molecul Cell Proteomics 2011 10 111.007948 10.1074/mcp.M111.007948
40. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. Ong'echa JMO, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago ASS, Hightower AW, Nahlen BL, Shi YP, AmJTrop Med Hyg 2003 68 590 597
41. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK, Proc Nat Acad Sci USA 2010 107 6958 6963 10.1073/pnas.1001323107 20351286
42. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull PC, Marsh K, Inf Immun 2009 77 1917 1923 10.1128/IAI.01358-08
43. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K, Malar J 2007 6 82 10.1186/1475-2875-6-82 17598897
44. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Akpogheneta OJ, Duah NO, Tetteh KKA, Dunyo S, Lanar DE, Pinder M, Conway DJ, Inf Immun 2008 76 1748 1755 10.1128/IAI.01333-07